


AMENDMENTS TO THE CLAIMS


1-12. (Cancelled)

13. (Currently Amended) A process, comprising:


contacting blood or a fraction thereof, wherein the blood or fraction thereof is in a non-diseased state, with a therapeutic substance selected from the group consisting of tetracycline



having the chemical formula _____, doxycycline having the



chemical formula _____, ~~vibramycin, terramycin~~




oxytetracycline having the chemical formula _____, and


salts thereof thereby increasing the level of cytokine receptors in the blood or the fraction thereof, wherein the cytokine receptors are selected from the group consisting of interleukin-1 receptors and tumor necrosis factor receptors; and

after the contacting, isolating the blood or the fraction thereof having the increased cytokine receptors thereby producing a composition suitable for administration for the treatment of a disease, condition or disorder.


14. (Previously Presented) The process of claim 13, wherein the contacting is *in vivo*.
15. (Previously Presented) The process of claim 13, wherein the contacting is *in vitro*.
16. (Previously Presented) The process of claim 13, wherein the cytokine receptors are increased at least three-fold relative to non-contacted blood or a fraction thereof.
17. (Cancelled)
18. (Previously Presented) The process of claim 13, further comprising processing the isolated blood or the fraction thereof by a process selected from the group consisting of: centrifugation, filtration, fractional precipitation, organic solvent precipitation, selective absorption, isoelectric precipitation, and chromatography.
19. (Previously Presented) The process of claim 18, wherein the blood or the fraction thereof includes a gamma-globulin fraction, a anti-hemophilia factor fraction, a albumin fraction, serum and plasma.
20. (Previously Presented) The process of claim 13, further comprising administering the composition to treat a disease, condition or disorder wherein the disease, condition or disorder is one of viral hemorrhagic diseases, sepsis, cachexia, rheumatoid arthritis, acute cardiovascular events, chronic myelogenous leukemia, transplanted bone marrow-induced graft-versus-host disease, septic shock, immune complex-induced colitis, cerebrospinal fluid inflammation, autoimmune disorders, multiple sclerosis, systemic inflammatory response syndrome, adult respiratory distress syndrome, acute liver failure, inflammatory bowel disease and Crohn's disease.
21. (Currently Amended) A process, comprising:
contacting blood *in vivo*, wherein the blood is in a non-diseased state, -with a therapeutic substance selected from the group consisting of tetracycline having the chemical formula



_____, doxycycline having the chemical formula



_____, vibramycin, terramycin oxytetracycline having



the chemical formula _____ and salts thereof thereby increasing the level of cytokine receptors in the blood, wherein the cytokine receptors are selected from the group consisting of interleukin-1 receptors and tumor necrosis factor receptors; after the contacting, collecting a portion of the blood; and after the collecting, processing the portion of the blood to isolate a blood fraction comprising cytokine receptors.

22. (Previously Presented) The process of claim 21, wherein the processing is selected from the group consisting of: centrifugation, filtration, fractional precipitation, organic solvent precipitation, selective absorption, isoelectric precipitation and chromatography.

23. (Cancelled)

24. (Previously Presented) The process of claim 21, wherein prior to the collecting, the number of cytokine receptors in the portion of the blood is increased by a least three-fold relative

to the portion of the blood prior to the contacting with the therapeutic substance.

25. (Previously Presented) The process of claim 21, wherein the blood or the fraction thereof includes a gamma-globulin fraction, a anti-hemophilia factor fraction, a albumin fraction, serum and plasma.

26. (Previously Presented) The process of claim 21, further comprising administering the blood or fraction thereof to treat a disease, condition or disorder wherein the disease, condition or disorder is one of viral hemorrhagic diseases, sepsis, cachexia, rheumatoid arthritis, acute cardiovascular events, chronic myelogenous leukemia, transplanted bone marrow-induced graft-versus-host disease, septic shock, immune complex-induced colitis, cerebrospinal fluid inflammation, autoimmune disorders, multiple sclerosis, systemic inflammatory response syndrome, adult respiratory distress syndrome, acute liver failure, inflammatory bowel disease and Crohn's disease.